CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious ...
NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, ...
HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a collaboration with UCB to provide a broad range of in vitro pharmacology ...
SAGE Teams with CNS Expert Steven Paul, M.D.; Secures $35 million Series A to Accelerate Treatments for CNS Conditions; Expects to Launch First of Several Clinical Programs in 2012 Boston, Mass. - ...
Two poster presentations at ACNP highlight new research on the fundamental biology of molecules targeting synaptic function in CNS disease Insights advance translational model supporting Gate’s lead ...
Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the ...
News Medical on MSN
Considerations for taking ASO discovery programs into animal models
insights from industrySusanne BackAssociate Director of Central Nervous System (CNS) PharmacologyCharles River Laboratories ...
In this interview, Dr. Susanne Back explains the growing role of antisense oligonucleotides (ASOs) in neuroscience drug discovery. She discusses their benefits, challenges in administration, in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback